S&C advised Biohaven Pharmaceutical in a registered offering of common shares that totaled approximately $250 million. The offering, which was completed on January 30, was structured as an underwritten block trade with Goldman Sachs acting as the sole underwriter.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca and Yale University.
The S&C team advising Biohaven is led by Robert Downes, the co-head of S&C’s Capital Markets Group. Davis Wang advised on tax matters.